(3R,5S)-5-Methoxymethyl-pyrrolidin-3-ol | 340740-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3R,5S)-5-Methoxymethyl-pyrrolidin-3-ol
• 英文别名: (3R,5S)-5-(Methoxymethyl)pyrrolidin-3-ol
• CAS: 340740-51-4
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: XUEHQBMFCHRSRL-NTSWFWBYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (2S,4R)-2-Methoxymethyl-4-trimethylsilanyloxy-pyrrolidine-1-carboxylic acid benzyl ester 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以86%的产率得到(3R,5S)-5-Methoxymethyl-pyrrolidin-3-ol
  参考文献：
  名称：

  Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use

  摘要：

  这项发明涉及由公式I表示的化合物，以及这些化合物的前药、药学上可接受的盐或溶剂，其中X、R1和R11如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给予公式I化合物来治疗哺乳动物的过度增殖性疾病的方法。

  公开号：

  US20040019065A1

文献信息

• COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：US20160090595A1

  公开（公告）日：2016-03-31

  Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
• COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES
  申请人：Aposense LTD.

  公开号：US20170100486A1

  公开（公告）日：2017-04-13

  A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA. The delivery system comprises conjugation of the macromolecule drug to a moiety that enables effective passage through the membranes. Respectively, novel compounds and pharmaceutical compositions are provided, utilizing said delivery system. In one aspect of the invention, the compounds may be utilized in medical practice, for example, in delivery of siRNA or antisense oligonucleotides across biological membranes for the treatment of medical disorders.
• US6833456B2
  申请人：——

  公开号：US6833456B2

  公开（公告）日：2004-12-21
• US9993563B2
  申请人：——

  公开号：US9993563B2

  公开（公告）日：2018-06-12
• Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use
  申请人：——

  公开号：US20040019065A1

  公开（公告）日：2004-01-29

  The invention relates to compounds represented by the formula I 1 and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R 1 and R 11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

  这项发明涉及由公式I表示的化合物，以及这些化合物的前药、药学上可接受的盐或溶剂，其中X、R1和R11如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给予公式I化合物来治疗哺乳动物的过度增殖性疾病的方法。